BDR in pact to make Gilead drug for Cipla

In late May, BDR had sought the approval of India’s drug regulator to make and sell remdesivir in India without entering into an arrangement with Gilead. The Mumbai-based company has now signed a contract to make the drug for Cipla, which is one of the licensed companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2ZUsK3H
via IFTTT